Document Top

  • VEGF is associated with aggressive disease

    VEGF in ovarian cancer

     

     

     More

  • GOG‐0218: treatment duration with Avastin

    Avastin front‐line in ovarian cancer

     

     

     More

  • ICON7: improved PFS with front‐ line Avastin

    GOG‐0218: front‐line Avastin has a manageable safety profile

      

     More

  • Avastin has a manageable safety profile

    ICON‐7: Avastin‐ related adverse events as previously reported

      

     More

 

Educational webcasts

A series of webcasts highlighting some of the key learning points from scientific and clinical data.
Experienced physicians and scientists share their thoughts on the development of anticancer agents and discuss the options available for the treatment of ovarian cancer

More

Patient Cases

Patient cases

Physicians share their experience and discuss treatment options for patients with ovarian cancer.
The case presentations are designed to provide an insight into clinical practice and treatment decisions supported by trial data.

More

  • Controlling angiogenesis to control tumour growth

    Controlling angiogenesis to control tumour growth

    Avastin precisely targets VEGF to inhibit angiogenesis for continuous tumour control

    View

  • Angiogenesis, VEGF and the MoA of Avastin

    Angiogenesis, VEGF and the MoA of Avastin

    Precise VEGF inhibition with Avastin is a proven anti-tumour strategy

    View

Watch more

  • Avastin in ovarian cancer

    Avastin in ovarian cancer

    Avastin front-line in women with advanced ovarian cancer (Prof Antonio González Martín)

    View

  • Inhibiting angiogenesis

    Inhibiting angiogenesis

    Inhibiting angiogenesis: a mechanistic evaluation (Prof Román Pérez‐Soler)

    View

Watch more

  • COMING SOON

    COMING SOON

    Patient case: Avastin in advanced ovarian cancer

    View

Watch more

Upcoming Conferences

  • USA
    AACR
    ,
    Chicago, IL, USA
    31 March 2012 - 04 April 2012
  • Spain
    EONS
    ,
    Valencia, Spain
    26-27 April 2012
  • Spain
    EACR
    ,
    Barcelona, Spain
    7-10 July 2012

More upcoming conferences

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel